{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:07:53Z","timestamp":1793725673451,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangzhou Baiyun District Dean's Fund Project","award":["BYY23011"],"award-info":[{"award-number":["BYY23011"]}]},{"name":"Guangzhou Health Science and Technology Project","award":["20242A011032"],"award-info":[{"award-number":["20242A011032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-025-04096-7","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T18:01:28Z","timestamp":1745776888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting"],"prefix":"10.1186","volume":"25","author":[{"given":"Tao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"4096_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20:5\u201321.","journal-title":"Diabetes Obes Metab."},{"key":"4096_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s001090000086","volume":"78","author":"MK Slifka","year":"2008","unstructured":"Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. J Mol Med. 2008;78:74\u201380. https:\/\/doi.org\/10.1007\/s001090000086.","journal-title":"J Mol Med."},{"issue":"4","key":"4096_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","volume":"132","author":"CC Chou","year":"2025","unstructured":"Chou CC, Pan SY, Sheen YJ, Lin JF, Lin CH, Lin HJ, et al. Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Study. Ophthalmology. 2025;132(4):381\u20138.","journal-title":"Ophthalmology."},{"issue":"8","key":"4096_CR4","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","volume":"142","author":"JT Hathaway","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732\u20139.","journal-title":"JAMA Ophthalmol."},{"issue":"4","key":"4096_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/bph.15683","volume":"179","author":"QN Cui","year":"2022","unstructured":"Cui QN, Stein LM, Fortin SM, et al. The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma. Br J Pharmacol. 2022;179(4):715\u201326.","journal-title":"Br J Pharmacol."},{"issue":"4","key":"4096_CR6","first-page":"424","volume":"14","author":"MC Berkovic","year":"2023","unstructured":"Berkovic MC, Strollo F. Semaglutide-eye-catching results. World J. Diabetes. 2023;14(4):424.","journal-title":"Diabetes."},{"key":"4096_CR7","doi-asserted-by":"crossref","unstructured":"Lusk JB, B MG, Li F. Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol. 2024;142(12):1173\u20134.","DOI":"10.1001\/jamaophthalmol.2024.4515"},{"issue":"1","key":"4096_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41433-021-01741-5","volume":"36","author":"A Sharma","year":"2022","unstructured":"Sharma A, Parachuri N, Kumar N, et al. Semaglutide and the risk of diabetic retinopathy\u2014current perspective. Eye. 2022;36(1):10\u20131.","journal-title":"Eye."},{"issue":"8","key":"4096_CR9","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/biomedicines9080926","volume":"9","author":"R Sim\u00f3","year":"2021","unstructured":"Sim\u00f3 R, Bogdanov P, Ramos H, et al. Effects of the topical administration of semaglutide on retinal neuroinflammation and vascular leakage in experimental diabetes. Biomedicines. 2021;9(8):926.","journal-title":"Biomedicines."},{"key":"4096_CR10","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.2147\/DDDT.S470826","volume":"18","author":"XD Yang","year":"2024","unstructured":"Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug Des Devel Ther. 2024;18:2555\u201370.","journal-title":"Drug Des Devel Ther."},{"key":"4096_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12325-020-01548-y","volume":"38","author":"A Shi","year":"2021","unstructured":"Shi A, Xie P, Nielsen LL, et al. Pharmacokinetics, safety and tolerability of once-weekly subcutaneous semaglutide in healthy Chinese subjects: a double-blind, phase 1, randomized controlled trial. Adv Ther. 2021;38:550\u201361.","journal-title":"Adv Ther."},{"key":"4096_CR12","doi-asserted-by":"publisher","first-page":"110605","DOI":"10.1016\/j.diabres.2023.110605","volume":"198","author":"A Li","year":"2023","unstructured":"Li A, Su X, Hu S, et al. Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2023;198:110605.","journal-title":"Diabetes Res Clin Pract."},{"key":"4096_CR13","doi-asserted-by":"publisher","unstructured":"Zhang J, Wang X, Zhou Y. Comparative analysis of semaglutide induced adverse reactions: Insights from FAERS database and social media reviews with a focus on oral vs subcutaneous administration. Front Pharmacol. 2024;15. https:\/\/doi.org\/10.3389\/fphar.2024.1471615.","DOI":"10.3389\/fphar.2024.1471615"},{"key":"4096_CR14","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s13300-019-00706-y","volume":"10","author":"S Nuhoho","year":"2019","unstructured":"Nuhoho S, Gupta J, Hansen BB, et al. Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1\u20132 oral antidiabetics: systematic review and network meta-analysis. Diabetes Ther. 2019;10:2183\u201399.","journal-title":"Diabetes Ther."},{"issue":"4","key":"4096_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsb\u00f8ll","year":"2018","unstructured":"Vilsb\u00f8ll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889\u201397.","journal-title":"Diabetes Obes Metab."},{"key":"4096_CR16","doi-asserted-by":"crossref","unstructured":"Kapoor I, Sarvepalli SM, D'Alessio D, et al, Hadziahmetovic M. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Surv Ophthalmol. 2023; 68(6):1071\u201383.","DOI":"10.1016\/j.survophthal.2023.07.002"},{"issue":"3","key":"4096_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/M22-2904","volume":"176","author":"SD Navaneethan","year":"2023","unstructured":"Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023;176(3):381\u20137.","journal-title":"Ann Intern Med."},{"issue":"4","key":"4096_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275\u201386.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4096_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajem.2024.01.010","volume":"78","author":"B Long","year":"2024","unstructured":"Long B, Pelletier J, Koyfman A, et al. GLP-1 agonists: A review for emergency clinicians. Am J Emerg Med. 2024;78:89\u201394.","journal-title":"Am J Emerg Med."},{"issue":"9","key":"4096_CR20","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, et al. Oral semaglutide versus subcutaneous liraglutide in type 2 diabetes: PIONEER 10 trial. Diabetes Care. 2019;42(9):1724\u201332. https:\/\/doi.org\/10.2337\/dc19-0749.","journal-title":"Diabetes Care."},{"key":"4096_CR21","doi-asserted-by":"publisher","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et\u00a0al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0.","DOI":"10.1016\/S0140-6736(21)00213-0"},{"issue":"9","key":"4096_CR22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Butler J, Borlaug BA, et al. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials. J Am Coll Cardiol. 2024;84(9):773\u201385. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.001.","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"4096_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40264-017-0589-z","volume":"41","author":"E Raschi","year":"2018","unstructured":"Raschi E, Poluzzi E, Salvo F, Koci A, Suling M, Antoniazzi S, et al. The US FDA Adverse Event Reporting System: A Key Contribution to Pharmacovigilance. Drug Saf. 2018;41(1):25\u201334. https:\/\/doi.org\/10.1007\/s40264-017-0589-z.","journal-title":"Drug Saf."},{"issue":"7","key":"4096_CR24","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.2337\/dc19-0441","volume":"42","author":"M Dahl","year":"2019","unstructured":"Dahl M, Hansen TW, Rasmussen LM, Rossing P, Parving HH. GLP-1 Receptor Agonists and Risk of Diabetic Retinopathy: A Nationwide Cohort Study. Diabetes Care. 2019;42(7):e111\u20132. https:\/\/doi.org\/10.2337\/dc19-0441.","journal-title":"Diabetes Care."},{"issue":"9","key":"4096_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMc1615712","volume":"376","author":"SP Marso","year":"2017","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2017;376(9):891\u20132. https:\/\/doi.org\/10.1056\/NEJMc1615712.","journal-title":"N Engl J Med."},{"issue":"3","key":"4096_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40262-021-01083-1","volume":"61","author":"JL Lau","year":"2022","unstructured":"Lau JL, Gupta S, Li L, Smith BP. Sex Differences in the Pharmacokinetics of Semaglutide: A Population Analysis. Clin Pharmacokinet. 2022;61(3):401\u201310. https:\/\/doi.org\/10.1007\/s40262-021-01083-1.","journal-title":"Clin Pharmacokinet."},{"key":"4096_CR27","doi-asserted-by":"publisher","unstructured":"Nian S, Cao J, Zhang Q, Yang X, Su Y, Liu Y. Estrogen Attenuates Diabetic Retinopathy by Inhibiting VEGF Signaling via Estrogen Receptor $$\\alpha$$. Diabetes. 2021;70(7):1615\u201327. https:\/\/doi.org\/10.2337\/db20-1053.","DOI":"10.2337\/db20-1053"},{"issue":"9","key":"4096_CR28","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.ophtha.2010.01.032","volume":"117","author":"R Klein","year":"2010","unstructured":"Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Relationship of Menopausal Hormone Therapy and Other Factors to the Risk of Diabetic Retinopathy in the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology. 2010;117(9):1746\u201352. https:\/\/doi.org\/10.1016\/j.ophtha.2010.01.032.","journal-title":"Ophthalmology."},{"issue":"4","key":"4096_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/jcph.1423","volume":"55","author":"C Kapitza","year":"2019","unstructured":"Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive ethinylestradiol\/levonorgestrel. J Clin Pharmacol. 2019;55(4):497\u2013504. https:\/\/doi.org\/10.1002\/jcph.1423.","journal-title":"J Clin Pharmacol."},{"issue":"9","key":"4096_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(9):653\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5.","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04096-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04096-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04096-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T18:01:30Z","timestamp":1745776890000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04096-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4096"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04096-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5868396\/v1","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on open-label data and does not contain any new studies conducted by authors on human participants or animals and does not require ethical approval.All the study participants provided their informed consent since there is no personal data, publication consent is not requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"248"}}